Literature DB >> 17889935

Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.

Fabio Stagno, Stefania Stella, Salvatore Berretta, Michele Massimino, Agostino Antolino, Rosario Giustolisi, Angelo Messina, Francesco Di Raimondo, Paolo Vigneri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17889935     DOI： 10.1016/j.leukres.2007.08.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  7 in total

Review 1.  Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Anna M Eiring; Michael W Deininger
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

2.  BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Authors:  Matthew S Zabriskie; Christopher A Eide; Srinivas K Tantravahi; Nadeem A Vellore; Johanna Estrada; Franck E Nicolini; Hanna J Khoury; Richard A Larson; Marina Konopleva; Jorge E Cortes; Hagop Kantarjian; Elias J Jabbour; Steven M Kornblau; Jeffrey H Lipton; Delphine Rea; Leif Stenke; Gisela Barbany; Thoralf Lange; Juan-Carlos Hernández-Boluda; Gert J Ossenkoppele; Richard D Press; Charles Chuah; Stuart L Goldberg; Meir Wetzler; Francois-Xavier Mahon; Gabriel Etienne; Michele Baccarani; Simona Soverini; Gianantonio Rosti; Philippe Rousselot; Ran Friedman; Marie Deininger; Kimberly R Reynolds; William L Heaton; Anna M Eiring; Anthony D Pomicter; Jamshid S Khorashad; Todd W Kelley; Riccardo Baron; Brian J Druker; Michael W Deininger; Thomas O'Hare
Journal:  Cancer Cell       Date:  2014-08-14       Impact factor: 31.743

Review 3.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

4.  The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Authors:  Christopher A Eide; Lauren T Adrian; Jeffrey W Tyner; Mary Mac Partlin; David J Anderson; Scott C Wise; Bryan D Smith; Peter A Petillo; Daniel L Flynn; Michael W N Deininger; Thomas O'Hare; Brian J Druker
Journal:  Cancer Res       Date:  2011-04-19       Impact factor: 12.701

5.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

Authors:  Thomas O'Hare; William C Shakespeare; Xiaotian Zhu; Christopher A Eide; Victor M Rivera; Frank Wang; Lauren T Adrian; Tianjun Zhou; Wei-Sheng Huang; Qihong Xu; Chester A Metcalf; Jeffrey W Tyner; Marc M Loriaux; Amie S Corbin; Scott Wardwell; Yaoyu Ning; Jeffrey A Keats; Yihan Wang; Raji Sundaramoorthi; Mathew Thomas; Dong Zhou; Joseph Snodgrass; Lois Commodore; Tomi K Sawyer; David C Dalgarno; Michael W N Deininger; Brian J Druker; Tim Clackson
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

Review 6.  New Developments in Chronic Myeloid Leukemia: Implications for Therapy.

Authors:  Sanaz Tabarestani; Abolfazl Movafagh
Journal:  Iran J Cancer Prev       Date:  2016-02-22

Review 7.  Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.

Authors:  Michele Massimino; Stefania Stella; Elena Tirrò; Chiara Romano; Maria Stella Pennisi; Adriana Puma; Livia Manzella; Antonino Zanghì; Fabio Stagno; Francesco Di Raimondo; Paolo Vigneri
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.